oral FXR agonist for NASH

robust in vivo PD, phase I HV study withdrawn

from prior FXR agonists

ACS Med. Chem. Lett

Bristol Myers Squibb, Princeton, NJ, USA


The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I study. The molecule exhibits potent in vitro and in…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: